Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Risk factors

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

= 0.75) of the variance in AD prevalence. Racial and ethnic minority status showed the highest importance value (0.848), far exceeding all other features (e.g., poor sleep ranked second with importance value of 0.153). This study confirmed upstream factors as being significant predictors of AD prevalence and racial and ethnic minority status as being the most important. From a policy perspective, efforts to reduce population levels of AD prevalence should consider addressing racial and ethnic disparities.

What this study adds

Evidence grade: Low

This artificial intelligence analysis found that racial and ethnic minority status had the highest importance value (0.848) among predictors of AD prevalence, far exceeding other features such as poor sleep. The study is about upstream predictors of AD prevalence and policy implications, not about treating, curing, or preventing Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Pronk, N. P., Wang, S., Woodard, C., Bhatt, T. S., & Arena, R. A. (2026). Multilevel prediction of Alzheimer's disease dementia in the United States: An artificial intelligence analysis. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring. https://doi.org/10.1002/dad2.70274

Vancouver

Pronk NP, Wang S, Woodard C, Bhatt TS, Arena RA. Multilevel prediction of Alzheimer's disease dementia in the United States: An artificial intelligence analysis. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring. 2026. doi:10.1002/dad2.70274. PMID: 41710069.

BibTeX

@article{pronk2026-41710069,
  author  = {Pronk, Nicolaas P. and Wang, Shuaijie and Woodard, Colin and Bhatt, Tanvi S. and Arena, Ross A},
  title   = {{Multilevel prediction of Alzheimer's disease dementia in the United States: An artificial intelligence analysis}},
  journal = {Alzheimer s \& Dementia Diagnosis Assessment \& Disease Monitoring},
  year    = {2026},
  doi     = {10.1002/dad2.70274},
  pmid    = {41710069},
  url     = {https://doi.org/10.1002/dad2.70274}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This artificial intelligence analysis found that racial and ethnic minority status had the highest importance value (0.848) among predictors of AD prevalence, far exceeding other features such as poor sleep. The study is about upstream predictors of AD prevalence and policy implications, not about treating, curing, or preventing Alzheimer's disease.

Study details

How this study scored 39/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 3 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 39 of 100.39 of 100 points earned61 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring)
Journal's citation record 1 / 4 Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring: journal h-index 86 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 1 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.5 citations a year over 2 year(s) since 2026
Impact for its field and year 3 / 6 Cited 4.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Ross A Arena: h-index 96 (OpenAlex, whole career)
Institution's track record 2 / 3 University of Minnesota: institution h-index 1,568 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 4 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41710069)
Free to read 2 / 2 Free to read
Total 39 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Risk factors from nearby years

Also in Risk factors

389 studies in the library are filed under Risk factors with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Risk factors hub.

Similar studies

More on Risk factors

See all studies in Risk factors →